Jasper Therapeutics Inc (JSPR)

04:14 AM

Jasper Shares Surge Following Encouraging Early Asthma Trial Data - MSN

04:14 AM

Apr 14, 2026

Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN

Apr 14, 2026

Apr 07, 2026

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Insider Monkey

Apr 07, 2026

Apr 07, 2026

JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 07, 2026

Apr 02, 2026

12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga

Apr 02, 2026

Apr 02, 2026

Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN

Apr 02, 2026

Apr 02, 2026

UBS Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Maintains Target Price $1.5 - Moomoo

Apr 02, 2026

Apr 01, 2026

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks

Apr 01, 2026

Apr 01, 2026

Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Australia

Apr 01, 2026

Apr 01, 2026

Citizens reiterates Jasper Therapeutics stock rating on CEO change - Investing.com

Apr 01, 2026

Apr 01, 2026

Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - TipRanks

Apr 01, 2026

Mar 31, 2026

Jasper Therapeutics stock gains 5% on clinical progress despite Q4 loss - Investing.com India

Mar 31, 2026

Mar 31, 2026

MINISO Group Holding Limited (MNSO) Reports Q4 Earnings - news.alphastreet.com

Mar 31, 2026

Mar 31, 2026

Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings - AlphaStreet

Mar 31, 2026

Mar 30, 2026

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - Bitget

Mar 30, 2026

Mar 30, 2026

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c) - TipRanks

Mar 30, 2026

Mar 30, 2026

Jasper Therapeutics (JSPR) 10-K focuses on briquilimab mast cell programs and funding needs - Stock Titan

Mar 30, 2026

Mar 30, 2026

JSPR: Strong clinical progress but increased net loss and lower cash reserves highlight funding needs - TradingView — Track All Markets

Mar 30, 2026

Mar 30, 2026

Jasper Therapeutics (NASDAQ: JSPR) posts $75.8M 2025 loss, cash at $28.7M - Stock Titan

Mar 30, 2026

Mar 30, 2026

Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Jasper Therapeutics 4Q Loss $9.1M >JSPR - moomoo.com

Mar 30, 2026

Mar 30, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 30, 2026

Mar 30, 2026

Jasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92 - MSN

Mar 30, 2026

Mar 30, 2026

Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88 - Defense World

Mar 30, 2026

Mar 29, 2026

Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab - Yahoo Finance

Mar 29, 2026

Mar 29, 2026

Jasper Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 29, 2026

Mar 28, 2026

10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey

Mar 28, 2026

Mar 27, 2026

JSPR Stock Price, Quote & Chart | JASPER THERAPEUTICS INC (NASDAQ:JSPR) - ChartMill

Mar 27, 2026

Mar 25, 2026

Jasper Therapeutics Inc (JSPR) Stock News & Articles - 24/7 Wall St.

Mar 25, 2026

Mar 24, 2026

Jasper Therapeutics stock surges on positive briquilimab trial data amid mast cell therapy race - AD HOC NEWS

Mar 24, 2026

Mar 23, 2026

UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25 - marketscreener.com

Mar 23, 2026

Mar 23, 2026

UBS initiates Jasper Therapeutics stock rating at Neutral on competition By Investing.com - Investing.com Canada

Mar 23, 2026

Mar 23, 2026

UBS initiates Jasper Therapeutics stock rating at Neutral on competition - Investing.com

Mar 23, 2026

Mar 22, 2026

If You Invested $1,000 in Jasper Therapeutics Inc (JSPR) - Stock Titan

Mar 22, 2026

Mar 20, 2026

Jasper Therapeutics stock surges on positive briquilimab trial data for mast cell diseases - AD HOC NEWS

Mar 20, 2026

Mar 13, 2026

JSPR Should I Buy - Intellectia AI

Mar 13, 2026

Mar 10, 2026

Jasper Therapeutics, Inc. (JSPRW) Competitors - Meyka

Mar 10, 2026

Mar 08, 2026

Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN

Mar 08, 2026

Mar 07, 2026

How Jasper Therapeutics Inc. stock compares to industry benchmarksQuarterly Portfolio Review & Weekly High Return Forecasts - Naître et grandir

Mar 07, 2026

Mar 07, 2026

Aug Opening: How Jasper Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Snapshot & Pattern Based Trade Signal System - Naître et grandir

Mar 07, 2026

Mar 05, 2026

Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 05, 2026

Mar 04, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Mar 04, 2026